Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate

Inclusion Criteria: * Males, age 18 to 65 years * Subjects with Severe hemophilia A with a documented plasma FVIII level of \<1% * ≥ 150 exposure days with FVIII concentrate(s) as supported by medical records Exclusion Criteria: * Evidence of current or past inhibitor antibody * History of any congenital or acquired coagulation disorders other than hemophilia A * Platelet count \<75,000/mm3 * Abnormal renal function (serum creatinine \>2 times the upper limit of the normal \[ULN\] range) * Active liver disease verified by medical history or persistently elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>5 times the ULN or severe liver disease as evidenced by, but not limited to any of the following: International Normalized Ratio (INR) \>1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.